YILI(SH:600887) Jing Ji Guan Cha Wang·2026-02-12 08:07Group 1 - The core point of the news is that Yili Co., Ltd. has made significant advancements in the probiotic industry, including the development of a new probiotic strain for infant food and a commitment to maintaining a high dividend payout ratio [1][3]. - Yili's self-developed probiotic strain YLGB-1496 has been included in the list of probiotics approved for infant food by the National Health Commission, marking a breakthrough in China's local probiotic industry [1]. - The company plans to maintain a dividend payout ratio of no less than 75% from 2025 to 2027 to enhance shareholder returns [1]. Group 2 - Yili's stock price has shown a downward trend over the past seven trading days, with a decline from 27.08 yuan to 26.61 yuan, representing a cumulative drop of 2.21% [2]. - The latest closing price on February 12 was 26.61 yuan, with a trading volume of approximately 9.18 billion yuan, indicating relatively low market activity [2]. - Institutional views on Yili remain neutral to slightly optimistic, with a target price of 34.55 yuan, suggesting an upside potential of about 28.58% from the current stock price [3].